Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/8/2025 | $50.00 | Buy | Stifel |
| 12/4/2024 | $80.00 | Buy | H.C. Wainwright |
| 9/23/2024 | $118.00 | Overweight | Morgan Stanley |
| 5/21/2024 | $65.00 | Overweight | JP Morgan |
| 4/9/2024 | $65.00 | Overweight | Cantor Fitzgerald |
| 10/19/2023 | $90.00 | Mkt Outperform | JMP Securities |
| 7/27/2023 | $58.00 | Overweight | Piper Sandler |
| 5/25/2023 | $34.00 → $41.00 | Buy | Jefferies |
SCHEDULE 13G - Structure Therapeutics Inc. (0001888886) (Subject)
8-K - Structure Therapeutics Inc. (0001888886) (Filer)
10-Q - Structure Therapeutics Inc. (0001888886) (Filer)
Preclinical studies with ACCG-2671 demonstrate potent target engagement, robust weight loss, favorable safety profile and PK properties supportive of once-daily dosing in humans ACCG-2671 is the most advanced oral small molecule amylin-based drug candidate, with Phase 1 study initiation expected by year end 2025 Company to host conference call today at 4:30 p.m. Eastern Time SAN FRANCISCO, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced the selection of its lead oral small molecule amylin receptor agonist, ACCG-2671. Amy
SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced that management will participate in a presentation and fireside chat, and host one-on-one meetings at the Jefferies London Healthcare Conference being held November 19-21, 2024, in London, UK. Jefferies London Healthcare Conference Format:Presentation and fireside chat Date/time:Wednesday, November 20 at 8:00 a.m. GMT The live and archived webcast will be accessible from the company's website at https://ir.structuretx.com/eve
First patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity Oral small molecule amylin receptor agonist development candidate expected to be selected by the end of 2024 Strong financial position with cash, cash equivalent and short-term investments of $915.3 million expected to fund projected operations and key clinical milestones through at least 2027 Conference Call to discuss GSBR-1290 ACCESS development program today at 4:30 p.m. ET SAN FRANCISCO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today
Stifel initiated coverage of Structure Therapeutics with a rating of Buy and set a new price target of $50.00
H.C. Wainwright initiated coverage of Structure Therapeutics with a rating of Buy and set a new price target of $80.00
Morgan Stanley initiated coverage of Structure Therapeutics with a rating of Overweight and set a new price target of $118.00
SAN FRANCISCO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced key leadership appointments to drive its next phase of development and operational success. Blai Coll, M.D., Ph.D., has been promoted to Chief Medical Officer, replacing Mark Bach, M.D., Ph.D. as part of a planned succession, effective September 18. Dr. Coll has served as Vice President of Clinical Development at Structure since 2022, leading the GSBR-1290 program, Structure's oral small molecule GLP-1 agonist that is planned to enter Phase
SAN FRANCISCO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced the appointment of Angus C. Russell to its board of directors. Mr. Russell previously served as Chief Executive Officer of Shire plc and brings more than 30 years of experience in building and scaling companies in the global biopharmaceutical industry. "Structure is at an important moment in its evolution as we prepare to advance our oral small molecule GLP-1 agonist, GSBR-1290, into late-stage clinical development for obesity," said Raymond Steve
Completed enrollment in 12-week Phase 2a study of oral GLP-1 receptor agonist, GSBR-1290 Topline data from Phase 2a and Phase 1b multiple ascending dose study of GSBR-1290 expected in latter half of fourth quarter 2023 SAN FRANCISCO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today reported financial results for the second quarter June 30, 2023, and highlighted recent corporate achievements. "We have continued our momentum and are on track to report topline data from our fully-enrolled Phase 2a study of GSBR-129
4 - Structure Therapeutics Inc. (0001888886) (Issuer)
3 - Structure Therapeutics Inc. (0001888886) (Issuer)
4 - Structure Therapeutics Inc. (0001888886) (Issuer)
SC 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)
SC 13G - Structure Therapeutics Inc. (0001888886) (Subject)
SC 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)
Preclinical studies with ACCG-2671 demonstrate potent target engagement, robust weight loss, favorable safety profile and PK properties supportive of once-daily dosing in humans ACCG-2671 is the most advanced oral small molecule amylin-based drug candidate, with Phase 1 study initiation expected by year end 2025 Company to host conference call today at 4:30 p.m. Eastern Time SAN FRANCISCO, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced the selection of its lead oral small molecule amylin receptor agonist, ACCG-2671. Amy
First patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity Oral small molecule amylin receptor agonist development candidate expected to be selected by the end of 2024 Strong financial position with cash, cash equivalent and short-term investments of $915.3 million expected to fund projected operations and key clinical milestones through at least 2027 Conference Call to discuss GSBR-1290 ACCESS development program today at 4:30 p.m. ET SAN FRANCISCO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today
Phase 2b ACCESS study designed to evaluate multiple doses up to 120 mg of GSBR-1290 over 36 weeks Comprehensive development program also includes Phase 2 ACCESS II study to evaluate even higher doses of GSBR-1290 over 36 weeks; first patient expected to be dosed by end of 2024 Topline data from both ACCESS and ACCESS II studies expected in the fourth quarter of 2025 Company to host conference call today at 4:30 p.m. Eastern Time SAN FRANCISCO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced the first pati